Immunic to Participate in Industry and Investor Conferences in November
MWN-AI** Summary
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, has announced its participation in key investor and industry conferences throughout November. The company’s leadership, including CEO Daniel Vitt, Ph.D., and Chief Scientific Officer Hella Kohlhof, Ph.D., will engage in partnering activities at the BIO-Europe conference, taking place from November 3-5 in Vienna, Austria. Interested parties can schedule meetings through the BIO-Europe partneringONE portal or by contacting Jessica Breu, the Vice President of Investor Relations.
Additionally, on November 19-20, Dr. Vitt and Jason Tardio, President and COO, will host one-on-one meetings in London in relation to the Jefferies Global Healthcare Conference. Again, meetings can be arranged through Jessica Breu.
Immunic is progressing a promising clinical pipeline led by its lead candidate, vidofludimus calcium (IMU-838), which is currently in Phase 3 clinical trials for relapsing multiple sclerosis. Top-line results are anticipated by the end of 2026, following initial positive Phase 2 results. This therapy has a dual-action mechanism, combining neuroprotective properties through its role as a Nurr1 activator while simultaneously offering anti-inflammatory benefits by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
The company is also advancing IMU-856, aimed at restoring intestinal barrier functions, showing potential for various gastrointestinal conditions, and IMU-381, a next-generation molecule in preclinical testing targeting gastrointestinal diseases.
Investors and stakeholders are encouraged to follow Immunic’s progress and strategic vision amidst an evolving landscape in biotechnology. For more information, visit their website at www.imux.com.
MWN-AI** Analysis
Immunic, Inc. (Nasdaq: IMUX) is positioning itself as a significant contender in the biotech sector with its focus on developing oral therapies for chronic inflammatory and autoimmune diseases. With participation slated for notable industry and investor conferences in November, the company presents an intriguing opportunity for investors.
The upcoming BIO-Europe conference, where key executives will engage in partnership discussions, may open doors for collaborations that could enhance Immunic's developmental capabilities. Such partnerships could facilitate faster market entry and bolster the credibility of their leading drug candidates, particularly vidofludimus calcium (IMU-838), which is in Phase 3 trials for relapsing multiple sclerosis. As public interest in innovative treatments for chronic conditions continues to surge, successful outcomes at these conferences could turn investor sentiment more favorable.
Additionally, the Jefferies Global Healthcare Conference will provide further opportunities for high-level discussions, particularly as Immunic anticipates the release of top-line data from its trials by late 2026. Investors should keep an eye on these events, as they could lead to news that directly impacts the company's stock performance and market position.
However, investors should remain cautious. Immunic's forward-looking statements carry inherent risks tied to the biotechnology sector, including regulatory hurdles and competition. The pending results from clinical trials, particularly for its flagship candidates, must be closely monitored as they will dictate future growth and market strategy.
In summary, while Immunic presents a compelling investment case, particularly with its robust pipeline, it is crucial to stay vigilant about developments from the upcoming conferences and broader market conditions that may influence the company’s trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November:
- November 3-5: BIO-Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Hella Kohlhof, Ph.D., Chief Scientific Officer and Jessica Breu, Vice President Investor Relations and Communications, will participate in partnering activities at this conference in Vienna, Austria. To schedule a meeting, please use the BIO-Europe partneringONE portal or contact Jessica Breu at: jessica.breu@imux.com.
- November 19-20: Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will be hosting one-on-one meetings in London in connection with the Jefferies Global Healthcare Conference - London. To schedule a meeting, please contact Jessica Breu at: jessica.breu@imux.com.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
SOURCE Immunic, Inc.
FAQ**
What updates can Immunic Inc. (IMUX) provide on the phase 3 clinical trials for vidofludimus calcium and how does it differentiate from other therapies for relapsing multiple sclerosis?
Can Immunic Inc. (IMUX) elaborate on the expected timeline for data release from the ongoing clinical trials and any potential implications for future funding or partnerships?
How does Immunic Inc. (IMUX) plan to leverage its proprietary technology targeting Sirtuin 6 (SIRT6) to expand its pipeline addressing gastrointestinal diseases beyond current indications?
In light of the current macroeconomic factors impacting the biotech industry, what strategies is Immunic Inc. (IMUX) employing to ensure its financial stability and continuity of clinical development programs?
**MWN-AI FAQ is based on asking OpenAI questions about Immunic Inc. (NASDAQ: IMUX).
NASDAQ: IMUX
IMUX Trading
-2.12% G/L:
$1.385 Last:
2,943,476 Volume:
$1.50 Open:
